Bibliography
- Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63(7):649-71; Review
- Holzer P, Ahmedzai SH, Niederle N, Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5(3):145-51; Review
- Smith K, Hopp M, Mundin G, Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20(4):427-39
- Mueller-Lissner S. Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther 2010;27(9):581-90; Review
- Mikus J. Combining opioid agonists and antagonists as a solution for opioid-induced constipation. Eur Gastroenterol Hepatol 2009;4(2):55-8; Review
- Reimer K, Hopp M, Zenz M, Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology 2009;83(1):10-17
- Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13(1):56-64
- Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24(12):3503-12
- Ahmedzai SH, Nauck F, Bar-Sela G, A randomised, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26(1):50-60
- Vondrackova D, Leyendecker P, Meissner W, Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9(12):1144-54
- Schutter U, Grunert S, Meyer C, Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26(6):1377-87
- Sandner-Kiesling A, Leyendecker P, Hopp M, Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64(6):763-74
- CPMP/QWP/604/96. Note for guidance on quality of modified release products: A: oral dosage forms, B: transdermal dosage forms section 1 (quality). The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; July 1999; London
- Guidance for industry. Extended release oral dosage forms: development, evaluation, and application of in vitro/ in vivo correlations. U.S. Food and Drug Administration (FDA); 10903 New Hampshire Avenue Silver Spring, MD 20993 1997
- Smith K, Hopp M, Mundin G, Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50(5):360-7
- Regenthal R, Krüger M, Richter M, Preiss R. Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. Hum Exp Toxicol 1998;17(11):593-7
- Smith K, Hopp M, Mundin G, Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008;30(11):2051-68
- United States Pharmacopeia 34, National Formulary, 29 May 2011, 278-285:711 Dissolution
- Wagner J. Correlation of in vivo with in vitro data. Theoretical and practical considerations. Drug Intell Clin Pharm 1970;4:160-5
- Loo J, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968;57:918-28
- Langenbucher F, Möller H. Correlation of in vitro drug release with in vivo response kinetics. Pharm Ind 1983;45(6):623-8
- Chan KK, Langenbucher F, Gibaldi M. Evaluation of in vivo drug release by numerical deconvolution using oral solution data as weighting function. J Pharm Sci 1987;76(6):446-50
- Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23(1):48-53